EX-10.2 3 a15-3271_1ex10d2.htm EX-10.2 [EXECUTION VERSION] REVENUE INTEREST AGREEMENT Dated as of November 12, 2014 among AXOGEN, INC., AXOGEN CORPORATION and THREE PEAKS CAPITAL S.A.R.L.Revenue Interest Agreement • May 5th, 2020 • New York
REVENUE INTEREST AGREEMENT Dated as of May 10, 2018 Between LA JOLLA PHARMA, LLC, as Product Sub and THE ENTITIES MANAGED BY HEALTHCARE ROYALTY MANAGEMENT, LLC IDENTIFIED HEREIN, collectively as InvestorRevenue Interest Agreement • May 14th, 2018 • La Jolla Pharmaceutical Co • Biological products, (no disgnostic substances) • New York
This REVENUE INTEREST AGREEMENT (this “Agreement”) dated as of May 10, 2018 (the “Effective Date”), is entered into by and between and the entities managed by HealthCare Royalty Management, LLC set forth on Annex I (collectively, the “Investor”), and La Jolla Pharma, LLC, a Delaware limited liability company (“Product Sub”).
REVENUE INTEREST AGREEMENTRevenue Interest Agreement • July 6th, 2011 • Sinobiomed Inc • Pharmaceutical preparations • Delaware
SITOA CORPORATION, a California corporation, (“Sitoa”) and Sinobiomed Inc. (d/b/a Sitoa Global Inc.), a Delaware corporation, (“STOA”) have agreed to establish this REVENUE INTEREST AGREEMENT (this “Agreement”), dated this 1st day of July, 2011, pursuant to which STOA will receive 100% of the revenues and service fees (the “Revenue Interest”) that Sitoa has a right to receive under that certain Master Services Agreement, effective as of April 8, 2010, by and between Sonsi, Inc., a Delaware corporation, (“Sonsi”) and Sitoa (the “Master Services Agreement”).
